Superior vena cava syndrome due to mediastinal adenomatous goitre

Katoh, Hiroshi; Enomoto, Takumo; Watanabe, Masahiko

doi:10.1136/bcr-2015-210634

Cited by 3 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thrombi associated with these catheters and parts of implanted devices (e.g., pacemaker leads) have emerged as a significant cause of SVCS and account for up to 30% of all cases [6,7]. Additional rare benign non-device-related causes of SVCS include mediastinal fibrosis, radiation fibrosis, retrosternal goiter, Bechet's syndrome, and iatrogenic causes [18][19][20].…”

Section: Etiology Of Svcsmentioning

confidence: 99%

Malignant Superior Vena Cava Syndrome: State of the Art

Patriarcheas¹,

Grammoustianou²,

Ptohis³

et al. 2022

Cureus

View full text Add to dashboard Cite

Superior vena cava syndrome (SVCS) is a clinical entity characterized by signs and symptoms arising from the obstruction or occlusion of the thin-walled superior vena cava (SVC) and can result in significant morbidity and mortality. Despite the rise of benign cases of SVCS, as a thrombotic complication of intravascular devices, it is most commonly seen secondary to malignancy as a consequence of thrombosis, direct invasion of tumor cells inside the vessel, or external compression. SVCS can be the initial presentation of a previously undiagnosed tumor in up to 60% of cases. Lung cancer and non-Hodgkin lymphoma (NHL) are responsible for up to 85%-90% of malignancy-related SVCS, while metastatic cancers account for approximately 10%. Herein, we review the pathophysiology, etiology, clinical presentation, diagnosis, and management of malignancy-related SVCS.

show abstract

Section: Etiology Of Svcsmentioning

confidence: 99%